Table 2.
Male Cancer Burden in North Carolina: Leading Sites by Race, By Measure
| White | ||||
|---|---|---|---|---|
| Incidence* | Prevalence** | Mortality* | YPLL*** | |
| Rank | Site Cases (Rate) | Site Persons | Site Deaths (Rate) | Site Years |
| 1 | Prostate | Prostate | Lung/Bronchus | Lung/Bronchus |
| 4253 (132.0) | 29 839 | 2521 (80.5) | 34 273 | |
| 2 | Lung/Bronchus | Colon/Rectum | Prostate | Colorectal |
| 3135 (101.1) | 9803 | 574 (21.4) | 8054 | |
| 3 | Colon/Rectum | Urinary Bladder | Colon/Rectum | Pancreas |
| 1765 (56.9) | 6495 | 585 (18.9) | 5502 | |
| 4 | Bladder | Lung/Bronchus | Pancreas | Prostate |
| 1133 (37.7) | 460 | 404 (12.8) | 4713 | |
| 5 | Melanoma | Melanoma | Leukemia | Leukemia |
| 920 (29.0) | 6,437 | 320 (10.8) | 4586 | |
| Top 5 (#) | 11 206 | 59 034 | 4404 | 57 128 |
| All Cancers (#) | 17 286 | 81 505 | 7111 | 88 113 |
| Top 5 (%) | 64.8% | 72.4% | 61.9% | 64.8% |
|
Minority | ||||
| Incidence* | Prevalence** | Mortality* | YPLL*** | |
| Rank | Site Cases (Rate) | Site Persons | Site Deaths (Rate) | Site Years |
| 1 | Prostate | Prostate | Lung/Bronchus | Lung/Bronchus |
| 1478 (214.5) | 9739 | 629 (93.1) | 8538 | |
| 2 | Lung/Bronchus | Colon/Rectum | Prostate | Prostate |
| 694 (101.0) | 2080 | 328 (62.0) | 2946 | |
| 3 | Colon/Rectum | Lung/Bronchus | Colon/Rectum | Colorectal |
| 420 (59.7) | 1353 | 184 (27.8) | 2577 | |
| 4 | Kidney | Kidney/Renal Pelvis | Pancreas | Pancreas |
| 173 (22.4) | 679 | 108 (15.6) | 1570 | |
| 5 | Oral Cavity | NH Lymphoma | Liver | Liver |
| 167 (20.7) | 588 | 76 (27.8) | 1146 | |
| Top 5 (#) | 2932 | 14 439 | 1325 | 16 777 |
| All Cancers (#) | 4251 | 18 998 | 2016 | 24 278 |
| Top 5(%) | 69.0% | 76.9% | 65.7% | 69.1% |
*
Incidence and mortality rates are age-adjusted to the US 2000 Census; Incidence data for breast cancer include in situ cases.
**
9.5-year prevalence estimates are used.
***
Data are for white and African American populations only.
Cancer sites ranked for each measure as follows: Incidence and mortality by count; prevalence by number of persons alive with a history of cancer; YPLL by total years of life lost. Rates for female breast, ovary, corpus uteri, and prostate are based on the gender-specific population.